Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Agios Pharmaceuticals announced that the FDA has accepted its supplemental New Drug Application for mitapivat, an oral pyruvate kinase activator aimed at treating sickle cell disease, granting it Priority Review status with a PDUFA goal date of November 1, 2026. If approved, mitapivat would be the first oral PK activator for this indication, built …
onsemi announced agreements to divest manufacturing facilities in Tarlac, Philippines and Mountain Top, Pennsylvania as part of its Fab Right strategy aimed at optimizing manufacturing footprint and improving cost efficiency. The divestitures are expected to generate annual cost savings of approximately $35 million by 2028 and ensure continuity thr…
Healthcare Realty Trust Incorporated, a leading owner and operator of medical outpatient buildings in the U.S., will release its second quarter 2026 earnings on July 30, 2026, followed by a conference call on July 31 to discuss results, company activities, and industry trends.
Plug Power announced that the Hunter Valley Hydrogen Hub project in Australia, developed by Orica, has reached final investment decision, advancing the deployment of Plug’s 50MW GenEco PEM electrolyzers. The project, the largest green hydrogen initiative in Australia to reach FID, will produce approximately 4,700 tonnes of renewable hydrogen annual…
Axsome Therapeutics has initiated dosing in the FOCUS-2 Phase 3 clinical trial to evaluate solriamfetol as a treatment for children aged 6 to under 12 with ADHD, complementing an ongoing adolescent trial (FOCUS-3). The double-blind, placebo-controlled study will assess efficacy and safety in approximately 468 patients. This program targets a signif…
Annovis Bio has fully enrolled 850 patients in its pivotal Phase 3 trial of buntanetap for early Alzheimer's disease, exceeding initial projections. The trial's dual primary endpoints will assess symptomatic and disease-modifying effects, with data readouts expected in Q1 2027 and Q1 2028 respectively. The company plans two New Drug Application sub…
Wrap Technologies, Inc. announced the launch of WrapShield, an autonomous defense and public safety platform that integrates advanced thermal polarimetric sensing technology from Frenel Imaging Ltd. The platform connects detection, AI-assisted decision-making, and response across public safety, defense, and critical infrastructure sectors. Starting…
Avalo Therapeutics announced its participation in the Leerink Partners Therapeutics Forum with management hosting investor meetings to discuss its clinical stage developments targeting the IL-1β pathway for immune-mediated inflammatory diseases. Their lead asset, abdakibart, showed positive Phase 2 topline data in hidradenitis suppurativa. The comp…
Aeluma, Inc., a US-based semiconductor company specializing in scalable photonic and electronic technologies, announced that its CEO Jonathan Klamkin will chair the Industry Program at the Optica Advanced Photonics Congress. Additionally, the company will present a technical paper on its scalable quantum dot laser technology targeted for AI datacom…
Kailera Therapeutics announced positive topline results from two Phase 3 trials conducted by Hengrui Pharma on their oral GLP-1 receptor agonist HRS-7535 (KAI-7535) in China. The obesity trial showed significant mean weight loss up to 11.1% at week 50, and the type 2 diabetes trial demonstrated HbA1c reductions outperforming the comparator dapaglif…
OKYO Pharma Limited, a Nasdaq-listed clinical-stage biopharmaceutical company, announced its participation in a virtual fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium. Company executives will discuss progress on their flagship drug urcosimod for neuropathic corneal pain (NCP), including successful phase 2 results and plans …
Teva Pharmaceutical Industries announced it will advance its investigational anti-interleukin-15 monoclonal antibody TEV-408 into a Phase 2b clinical trial for vitiligo following encouraging Phase 1b study outcomes. The Phase 1b data showed that TEV-408 was well tolerated and led to improvement in skin pigmentation among patients with active or sta…
Aqua Metals, Inc. advances to final site diligence and negotiations for Headwaters ARC, a large-scale commercial battery recycling and critical minerals recovery facility in the Midwest, aiming to serve expanding lithium iron phosphate (LFP) battery manufacturing hubs. The phased project will start with battery preprocessing and black mass producti…
Nuvini Group Limited announced the full repayment of its R$61 million non-convertible debenture facility, marking the culmination of a multi-year deleveraging effort. This repayment removes associated covenants and liens, enhancing the company's capital structure and enabling greater flexibility to pursue its acquisition strategy across Latin Ameri…
Aclarion, Inc., a healthcare technology company specializing in biomarker-driven diagnostics for chronic low back pain, announced that Texas Spine Care Center has joined its CLARITY clinical trial. The CLARITY trial is a multi-center, randomized study evaluating Aclarion's Nociscan platform designed to identify painful discs in patients with chroni…
Kymera Therapeutics announced the appointment of Elizabeth Laws, Ph.D., as Senior Vice President and Global Program Team Leader for KT-621, an innovative oral STAT6 degrader targeting immunological diseases. Dr. Laws brings extensive experience from Sanofi, including leadership in immunology drug development and commercialization. KT-621 is advanci…
Aquestive Therapeutics announced its participation in the Leerink Partners Therapeutics Forum focusing on immunology, inflammation, and metabolism, where management will hold one-on-one investor meetings. The company is advancing its proprietary medicines using innovative oral film delivery technology and developing new therapies such as Anaphylm™ …
AC Immune SA announces three presentations at the Alzheimer's Association International Conference 2026 showcasing its cutting-edge Morphomer®-based therapies and diagnostics for neurodegenerative diseases, including new imaging agents and novel inhibitors currently in clinical and preclinical development.
ImageneBio, a Nasdaq-listed clinical-stage biotechnology company, announced the appointment of Matt Robbins as General Counsel effective July 7, 2026. Robbins brings over 15 years of legal experience in life sciences, including corporate governance, securities, and transactional expertise, to support ImageneBio's ongoing Phase 2 clinical programs f…
Fury Gold Mines Limited has commenced its 2026 drilling program at the Committee Bay gold project in Nunavut, Canada. The program includes approximately 5,000 meters of diamond drilling focused on expanding the mineral resources at the Three Bluffs deposit and the Antler prospect. The company aims to grow its gold ounces, enhance geological underst…
A report on Tuesday said DeepSeek is developing a custom semiconductor for AI inference workloads, a project that could reduce its reliance on Nvidia and Huawei chips. Nvidia shares dipped 1.6% in premarket trading by 06:59 ET (10:59 GMT) after the report. The effort, which dates back about a year, is still at an early stage but has involved discus…
Boeing's path back to normalized production is the most actionable lever left for the stock. This trade idea buys into measurable improvements on the factory floor and the backlog cadence, with a defined entry at $220, a $280 target and a $190 stop.
Bank of America reinstated coverage of Adobe with an Underperform rating and a $190 price objective, arguing that generative AI threatens Adobe’s competitive position even as the stock trades near the low end of its historical valuation. The bank’s valuation is based on 7 times projected 2027 EV/FCF, below the roughly 9.7-times peer average, and it…
Liquidity Services (NASDAQ:LQDT), a leading global provider of e-commerce marketplaces focused on surplus assets and the circular economy, announced it will report its Q3 fiscal 2026 results on August 6, 2026, before market open. Management will host a conference call to discuss results with investors and the public, alongside a live webcast and re…
Latvia's Foreign Minister Baiba Braze said the United States has a "really invested interest" in keeping military forces stationed in Europe, as NATO members await the outcome of a six-month U.S. review of troop deployments. Speaking in Ankara ahead of a NATO summit, Braze emphasized that Washington is not simply seeking to withdraw and highlighted…
